C2I Alumni, LayerBio Inc., Awarded $1.2 Million from NIH to Develop Sustained-Release Glaucoma Drug

Congratulations to our alumni, LayerBio Inc., for being awarded $1.2 million SBIR grant to develop their sustained-release formula of the glaucoma drug travoprost.

Glaucoma is the leading cause of irreversible blindness worldwide, and an estimated 2.2 million people in the U.S. suffer from glaucoma. Current treatment (topical eye drops) has limited effectiveness in preventing the progression of glaucoma.

"Sustained-release formulations offer an important alternative to eye drops, because they provide around-the-clock coverage for patients suffering for glaucoma," said Dr. Ken Mandell, LayerBio's Founder and CEO. "They also overcome the issue of dosing noncompliance, a common problem among glaucoma patients" added Dr. Mandell. LayerBio's sustained-release glaucoma drug is based on a PolyNet™ platform invented by Dr. Mandell and co-founder Aleks White of LayerBio.

The C2I team wishes you good luck in your future endeavors!

Access the full article here.